Capsule summary

Increasing evidence suggests pernio-like lesions are cutaneous manifestations of COVID-19.

• In the BE ABLE 2 study, bimekizumab demonstrated high response rates maintained through week 60, with a substantial proportion achieving complete skin clearance, and was generally well tolerated. • These data further support dual neutralization of IL-17A and IL-17F…